Cingulate INC Form 4 insider transactions

Shane J. Schaffer, Chief Executive Officer and a Director of Cingulate Inc., reported multiple transactions in common stock on July 16, 2026.

Bryan Wade Downey, EVP & Chief Commercial Officer of Cingulate Inc., reported multiple transactions in common stock on July 16, 2026.

Bryan Jay Lawrence, a Director of Cingulate Inc., received 20,000 shares of common stock on July 16, 2026.

Matthew Brams, EVP and Chief Medical Officer of Cingulate Inc., reported multiple transactions in common stock on July 16, 2026.

Thomas Jeffrey Hargroves, a Director of Cingulate Inc., received 20,000 shares of common stock on July 16, 2026.

Jennifer L. Callahan, EVP and CFO of Cingulate Inc., reported multiple transactions in common stock on July 16, 2026.

Peter J. Werth, a Director of Cingulate Inc., received 20,000 shares of common stock on July 16, 2026.

Raul R. Silva, EVP and CSO of Cingulate Inc., reported multiple transactions in common stock on July 16, 2026.

Raul R. Silva, EVP and CSO of Cingulate Inc., was granted stock options for 3,885 shares of common stock.

Director Thomas Jeffrey Hargroves acquired 97,276 shares and 77,821 warrants of Cingulate Inc. through a private placement.

Cingulate Inc. EVP and CSO Raul Silva was granted 3,422 stock options as part of his employment agreement.

Cingulate Inc.'s SVP and CFO, Jennifer L. Callahan, acquired common stock and warrants through a private placement transaction.

Cingulate Inc. Director and 10% owner Peter J. Werth acquired additional common stock and warrants through a private placement.

Cingulate Inc.'s EVP and Chief Medical Officer, Matthew Brams, acquired common stock and warrants through a private placement on February 6, 2026.

Cingulate Inc.'s CEO and Director, Shane J. Schaffer, acquired common stock and warrants through a private placement, increasing his indirect beneficial ownership.

Cingulate Inc.'s EVP and CSO, Raul R. Silva, was granted 6,625 stock options with an exercise price of $4.34, effective December 31, 2025.

Cingulate Inc.'s Executive Vice President and Chief Scientific Officer, Raul R. Silva, was granted 7,334 stock options with an exercise price of $3.92 per share.

Cingulate Inc.'s Chief Commercial Officer, Bryan Wade Downey, was granted 30,000 stock options with an exercise price of $3.8.

Cingulate Inc.'s Chief Legal Officer and Chief Compliance Officer, Nilay Dahyabhai Patel, was granted 30,000 stock options with an exercise price of $4.51, vesting over four years.

Cingulate Inc.'s Executive Vice President and Chief Scientific Officer, Raul R. Silva, was granted 51,500 stock options with an exercise price of $4.42, vesting over a four-year period.

Cingulate Inc.'s Executive Vice President and Chief Operating Officer, Laurie Myers, was granted 31,000 stock options with an exercise price of $4.42, vesting over a four-year period.

Cingulate Inc.'s Chief Executive Officer and Director, Shane J. Schaffer, has been granted 199,500 stock options with an exercise price of $4.42, aligning executive incentives with long-term shareholder value.

Cingulate Inc.'s Senior Vice President and Chief Financial Officer, Jennifer L. Callahan, was granted 64,500 stock options with an exercise price of $4.42, vesting over a four-year period.

Cingulate Inc. has granted 52,500 stock options to its EVP and Chief Medical Officer, Matthew Brams, with an exercise price of $4.42 per share, vesting over a four-year period.

Cingulate Inc.'s Executive Vice President and Chief Scientific Officer, Raul R. Silva, acquired 2,000 stock options with exercise prices of $4.30 and $4.07, set to expire in 2035.

Cingulate Inc. Director Jeffrey S. Ervin was granted 15,000 stock options with an exercise price of $4.14, aligning his interests with shareholder value.

Cingulate Inc. Director John A. Roberts was granted 15,000 stock options with an exercise price of $4.14, as disclosed in a recent SEC Form 4 filing.

Cingulate Inc. Director Lawrence Bryan Jay has been granted 15,000 stock options, aligning his interests with the company's future performance.

Cingulate Inc. Director Peter J. Werth was granted 15,000 stock options with an exercise price of $4.14, aligning his interests with shareholder value.

Jennifer L. Callahan, SVP and CFO of Cingulate Inc., reports the acquisition of stock options.